Stocks
Forward Pharma A/SFWP
HealthcareBiotechnology
A clinical-stage biopharmaceutical company developing FP187, a proprietary formulation of dimethyl fumarate, for the treatment of inflammatory and neurological diseases. Its primary focus has been on psoriasis and progressive multiple sclerosis, though regulatory setbacks have limited near-term commercial prospects. Investors track the stock for its intellectual property litigation outcomes and potential partnership opportunities.
Congressional Interest in Forward Pharma A/S (FWP)
1 member of Congress has disclosed 1 trade in Forward Pharma A/S (FWP), a Healthcare company. The buy/sell breakdown shows 0 purchases versus 1 sale, indicating net selling pressure from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
1
Unique Politicians
1
Buys
0
Sells
1
Who in Congress Is Trading FWP?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2017-05-23 | MICHAEL T. MCCAUL | sell | $15K-$50K |